Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study

Annals of the Rheumatic Diseases

Volumn 74, Issue 4, 2015, Pages 718-723

  Möller, Burkhard ^a   Pruijm, Menno ^b   Adler, Sabine ^a   Scherer, Almut ^c   Villiger, Peter M ^a   Finckh, Axel ^d  

^a UNIVERSITY OF BERN   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c SCQM Foundation   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOOXYGENASE 2; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LONG TERM EXPOSURE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTRATION; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; DOSE RESPONSE; MALE; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; STATISTICS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; STATISTICS AS TOPIC;

EID: 84925645152     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204078     Document Type: Article

References (41)

1. Evans JM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM 1995; 88: 551-7.
2. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
3. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675-9.
4. Toto RD, Anderson SA, Brown-Cartwright D, et al. Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int 1986; 30: 760-8.
5. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488-96.
6. Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45: 531-9.
7. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet 2010; 376: 173-9.
8. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-Analysis. BMJ 2011; 342: C7086.
9. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: Summary and recommendations to the scientific advisory board of the national kidney foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996; 27: 162-5.
10. Plantinga L, Grubbs V, Sarkar U, et al. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med 2011; 9: 423-30.
11. Risser A, Donovan D, Heintzman J, et al. NSAID prescribing precautions. Am Fam Physician 2009; 80: 1371-8.
12. Ziegler S, Huscher D, Karberg K, et al. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: Results from the National Database of the German Collaborative Arthritis Centres. Ann Rheum Dis 2011; 69: 1803-8.
13. Hippisley-Cox J, Coupland C. Predicting the risk of chronic Kidney Disease in men and women in England and Wales: Prospective derivation and external validation of the QKidney Scores. BMC Fam Pract 2010; 11: 49.
14. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39: 723-31.
15. Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 2006; 69: 2155-61.
16. Uitz E, Fransen J, Langenegger T, et al. Clinical quality management in rheumatoid arthritis: Putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis. Rheumatology (Oxford) 2000; 39: 542-9.
17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
18. Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010; 62: 1576-82.
19. Neovius M, Simard JF, Askling J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011; 70: 624-9.
20. Inker LA, Levey AS. Pro: Estimating GFR using the chronic kidney disease epidemiology collaboration (CKD-EPI) 2009 creatinine equation: The time for change is now. Nephrol Dial Transplant 2013; 28: 1390-6.
21. Delanaye P, Pottel H, Botev R, et al. Con: Should we abandon the use of the MDRD equation in favour of the CKD-EPI equation? Nephrol Dial Transplant 2013; 28: 1396-403.
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
23. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
24. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
25. Whelton A, Lefkowith JL, West CR, et al. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int 2006; 70: 1495-502.
26. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
27. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923-36.
28. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
29. Mauer M, Drummond K. The early natural history of nephropathy in type 1 diabetes: I. Study design and baseline characteristics of the study participants. Diabetes 2002; 51: 1572-9.
30. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: Meta-Analysis of randomized trials. JAMA 2006; 296: 1619-32.
31. Bellomo G, Venanzi S, Verdura C, et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010; 56: 264-72.
32. Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 2003; 42: 234-44.
33. Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004; 164: 1519-24.
34. Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med 1983; 308: 357-62.
35. Winkelmayer WC, Waikar SS, Mogun H, et al. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med 2008; 121: 1092-8.
36. Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: Nested case-control study. BMJ 2013; 346: E8525.
37. Hyrich K, Symmons D, Watson K, et al. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: Results from a national patient register. Ann Rheum Dis 2006; 65: 895-8.
38. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: A population-based study. Arthritis Rheum 2005; 52: 722-32.
39. Michels WM, Grootendorst DC, Verduijn M, et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010; 5: 1003-9.
40. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 2007; 82: 143-56.
41. Kristman V, Manno M, Cote P. Loss to follow-up in cohort studies: How much is too much? Eur J Epidemiol 2004; 19: 751-60.